Press releases
Browse LEO Pharma’s global press releases intended for media.
Press releases issued by our local operating companies can be viewed on our market websites.
-
DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases
DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases Munich, Germany, and Ballerup, Denmark, 5 February 2025 – DEBRA Research GmbH, a non-profit…
-
LEO Pharma Announces Changes to Executive Leadership
LEO Pharma Announces Changes to Executive Leadership Ballerup, 29 January 2025 – Today, LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr…
-
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases FOSTER CITY, Calif and BALLERUP, Denmark, January…
-
LEO Pharma gears for growth with senior leadership changes
LEO Pharma gears for growth with senior leadership changes LEO Pharma is excited to announce strategic leadership changes to bolster growth, further professionalize the organization, and strengthen its…
-
LEO Pharma commits to net-zero greenhouse gas emissions by 2050
LEO Pharma commits to net-zero greenhouse gas emissions by 2050 A net-zero target is a natural continuation of our current commitments to run a sustainable business, LEO Pharma…
-
LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year
LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year Ballerup, Denmark, 26 August, 2024 – During the first six months of 2024,…
-
Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis
Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis MADISON, NEW JERSEY, August 21, 2024 – Timber Pharmaceuticals Inc.,…
-
Change in the Board of Directors of LEO Pharma
Change in the Board of Directors of LEO Pharma Ballerup, Denmark, July 31, 2024 – Today, LEO Pharma A/S announced that non-executive director Jan van de Winkel has decided…
-
LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales
LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales Ballerup, Denmark, 31 October, 2024 – In the first nine months of 2024, LEO Pharma delivered…
-
LEO Pharma announces changes to its Global Leadership Team
LEO Pharma announces changes to its Global Leadership Team LEO Pharma today announced that Nathalie Daste, Executive Vice President of Global People & Corporate Affairs, has decided to…
Media Inquiries
Head of Media
+4530502014
JEILK@leo-pharma.com
SVP, Head of Corporate Communications
+4529407016
ANMRN@leo-pharma.com
Media Manager
+4553748849
CHBUN@leo-pharma.com
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Our press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request. For updated information about clinical trials, please visit https://clinicaltrials.gov/.